Exelixis Inc. buy klostergang
Start price
29.01.19
/
50%
€20.91
Target price
04.11.21
€35.18
Performance (%)
-11.66%
End price
17.06.21
€18.47
Summary
This prediction ended on 17.06.21 with a price of €18.47. The price of Exelixis Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -11.66%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Exelixis Inc. | -7.404% | -7.404% | 5.694% | 132.867% |
| iShares Core DAX® | 0.734% | 1.458% | 17.980% | 65.292% |
| iShares Nasdaq 100 | -2.686% | -0.146% | 3.810% | 97.467% |
| iShares Nikkei 225® | -2.261% | -2.729% | 11.679% | 39.755% |
| iShares S&P 500 | -1.346% | 0.467% | 1.970% | 61.093% |
Comments by klostergang for this prediction
In the thread Exelixis Inc. diskutieren
klostergang stimmt der Buy-Einschätzung von stratec zu
klostergang stimmt am 29.01.2018 der Buy-Einschätzung von stratec mit dem Kursziel 34$ zu.
Überschrift: EXEL is currently becoming a key player in the kidney cancer space
Update:
The stock sold off after fourth-quarter earnings, but the long-term thesis appears intact as label expansion for cabozantinib and other bullish drivers should kick in in the medium term. Near-term weakness, long-term outperformance is my initial impression.